Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey

被引:35
|
作者
Moon, Joon Ho [1 ]
Koo, Bo Kyung [1 ,2 ]
Kim, Won [1 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Metropolitan Govt, Boramae Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea
[3] Seoul Metropolitan Govt, Boramae Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Non-alcoholic fatty liver disease; Sarcopenia; Mortality; Nationwide survey; FIBROSIS STAGE; ASSOCIATION; DIAGNOSIS; RISK; MANAGEMENT; AGE; INFLAMMATION; FEATURES; OUTCOMES;
D O I
10.1002/jcsm.12719
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background Sarcopenia is an independent risk factor not only for advanced-stage non-alcoholic fatty liver disease (NAFLD) but also for mortality. We investigated the association of sarcopenia and/or NAFLD with mortality among the Korean general population. Methods Individuals aged 35-75 years without any history of cancer, ischaemic heart disease, ischaemic stroke, or secondary causes of chronic liver disease were selected from the Korean National Health and Nutrition Examination Surveys from 2008 to 2015. Their mortality data until December 2018 were retrieved from the National Death Registry. NAFLD and sarcopenia were defined by hepatic steatosis index and appendicular skeletal muscle mass divided by body mass index (BMI), respectively. Results A total of 28 060 subjects were analysed [mean age, 50.6 (standard error, 0.1) years, 48.2 (0.3) % men]; the median follow-up duration was of 6.8 (interquartile range, 4.8, 8.4) years. NAFLD predicted mortality after adjustment for age, sex, BMI, hypertension, dyslipidaemia, and smoking (HR 1.32, 95% CI 1.03-1.70), but this prediction lost its statistical significance after additional adjustment for diabetes mellitus. In contrast, NAFLD with advanced fibrosis independently increased the risk of mortality after adjustment for all covariates (HR 1.68, 95% CI 1.02-2.79). Stratified analysis revealed that NAFLD and sarcopenia additively increased the risk of mortality as an ordinal scale (HR 1.46, 95% CI 1.18-1.81, P for trend = 0.001). The coexistence of NAFLD and sarcopenia increased the risk of mortality by almost twice as much, even after adjustment for advanced fibrosis (HR 2.18, 95% CI 1.38-3.44). Conclusions Concurrent NAFLD and sarcopenia conferred a two-fold higher risk of mortality. The observation that NAFLD and sarcopenia additively increase mortality suggests that risk stratification would be helpful in predicting mortality among those with metabolic derangement.
引用
收藏
页码:964 / 972
页数:9
相关论文
共 50 条
  • [1] Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease
    Golabi, Pegah
    Gerber, Lynn
    Paik, James M.
    Deshpande, Rati
    de Avila, Leyla
    Younossi, Zobair M.
    JHEP REPORTS, 2020, 2 (06)
  • [2] Non-alcoholic fatty liver disease
    Maurice, James
    Manousou, Pinelopi
    CLINICAL MEDICINE, 2018, 18 (03) : 245 - 250
  • [3] Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: a Korean nationwide survey
    Kang, Sunyoung
    Moon, Min Kyong
    Kim, Won
    Koo, Bo Kyung
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2020, 11 (05) : 1232 - 1241
  • [4] Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study
    Roh, Eun
    Hwang, Soon Young
    Yoo, Hye Jin
    Baik, Sei Hyun
    Lee, Jin-Hee
    Son, Sang Joon
    Kim, Hyeon Ju
    Park, Yong Soon
    Lee, Sam-Gyu
    Cho, Be Long
    Jang, Hak Chul
    Kim, Bong Jo
    Kim, Miji
    Won, Chang Won
    Choi, Kyung Mook
    HEPATOLOGY INTERNATIONAL, 2022, 16 (03) : 545 - 554
  • [5] Non-alcoholic fatty liver disease in patients with chylomicronemia syndromes
    De Villers-Lacasse, Ariane
    Paquette, Martine
    Baass, Alexis
    Bernard, Sophie
    JOURNAL OF CLINICAL LIPIDOLOGY, 2023, 17 (04) : 475 - 482
  • [6] Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study
    Eun Roh
    Soon Young Hwang
    Hye Jin Yoo
    Sei Hyun Baik
    Jin-Hee Lee
    Sang Joon Son
    Hyeon Ju Kim
    Yong Soon Park
    Sam-Gyu Lee
    Be Long Cho
    Hak Chul Jang
    Bong Jo Kim
    Miji Kim
    Chang Won Won
    Kyung Mook Choi
    Hepatology International, 2022, 16 : 545 - 554
  • [7] Management of non-alcoholic fatty liver disease in patients with sarcopenia
    Hsu, Ching-Sheng
    Kao, Jia-Horng
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (02) : 221 - 233
  • [8] The growing burden of non-alcoholic fatty liver disease on mortality
    Cho, Ju-Yeon
    Sohn, Won
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (02) : 374 - 376
  • [9] Impact of Sarcopenia on Non-Alcoholic Fatty Liver Disease
    Iwaki, Michihiro
    Kobayashi, Takashi
    Nogami, Asako
    Saito, Satoru
    Nakajima, Atsushi
    Yoneda, Masato
    NUTRIENTS, 2023, 15 (04)
  • [10] Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort
    Simon, Tracey G.
    Roelstraete, Bjorn
    Hagstrom, Hannes
    Sundstroem, Johan
    Ludvigsson, Jonas F.
    GUT, 2022, 71 (09) : 1867 - 1875